

Referral Status:	MRN:
<input type="checkbox"/> New referral	<input type="checkbox"/> Order change
<input type="checkbox"/> Order Renewal	
Patient preferred clinic:	

Tocilizumab Unspecified Plan of Treatment for Rheumatology

PATIENT DEMOGRAPHICS:

Date of Referral:	Patient's Phone:
Patient Name:	Address:
Date of Birth:	City, State, Zip:
Height in inches:	Weight: LB or KG
Gender:	Allergies:
	<input type="checkbox"/> See list <input type="checkbox"/> NKDA

DIAGNOSIS: (PLEASE COMPLETE 2ND AND 3RD DIGITS TO COMPLETE ICD 10 FOR BILLING)

M05._____ - Rheumatoid Arthritis with Rheumatoid factor	M31.6 - Other Giant Cell Arteritis
M06._____ - Rheumatoid Arthritis without Rheumatoid factor	M31.5 - Giant cell Arthritis with Polymyalgia Rheumatica
_____ - Other:	

REQUESTED DOCUMENTATION:

1	Insurance information
2	Most recent History & Physical
3	Full medication list / Tried and failed therapies
4	REQUIRED: TB screening for new start
5	HBV screening/labs as required by payor
6	Recent CBC with diff and LFTs

PREVIOUS ADMINISTRATION: HAS THIS PATIENT TAKEN THIS MEDICATION BEFORE?

IF NO:	IF YES:
PLEASE STATE REQUIRED WASHOUT FROM PREVIOUS THERAPY:	LAST INFUSION DATE:
	NEXT INFUSION DATE:
	IF ORDER CHANGE:
	Continue current order until insurance approved

MEDICATION ORDERS:

PREMEDICATION TO BE ADMINISTERED 30 MINUTES PRIOR TO ADMINISTRATION AS SELECTED

NOTE: Patient may be ineligible to receive tocilizumab if receiving antibiotics for active infectious process, antifungal therapy, active fever and/or suspected infection, new-onset or deterioration neurological changes, new-onset abdominal symptoms, and/or surgery.

IV	Diphenhydramine	25mg	50mg	
	Methylprednisolone	40mg	125mg	Other:
	Famotidine	20mg	40 mg	
	Other:			

PO	Acetaminophen	325mg	500mg	650mg	1000mg
	Famotidine	20mg	40mg		
	Diphenhydramine	25mg	50mg		
	Fexofenadine	60mg	180mg		
	Cetirizine	10mg			
	Loratadine	10mg			
	Other:				

SPECIFIC MEDICATION:

<input type="checkbox"/> Actemra®	<input type="checkbox"/> Any tocilizumab biosimilar may be used according to payer guidelines
<input type="checkbox"/> Tyenne®	

LAB ORDERS:

CBC with diff, platelets, ALT and AST prior to first dose, at 2nd infusion, and then every 12 weeks.

LAB PARAMETERS:

On Initiation: ANC > 2000mm³; AST/ALT < 1.5 x ULN
 Maintenance: **If ANC** is 500 to 1000 cells/mm³, hold dose and notify referring MD. When ANC >1000 cells/mm³ therapy may be resumed. **If ANC** < 500 cells/mm³, then discontinue and notify referring MD. **If Platelet count** 50,000 to 100,000 cells/mm³, hold dose. When platelet count is > 100,000 cells/mm³, therapy may be resumed. **If Platelet count** is <50,000 cells/mm³, then discontinue and notify referring MD. **If AST/ALT** are > 3-5 x upper limit normal HOLD dose and notify referring MD

Tocilizumab doses exceeding 800mg are not recommended.

Prescriber confirms that the patient has been evaluated and screened for the presence of hepatitis B virus (HBV) prior to initiating treatment. Prescriber to monitor patient for symptoms of HBV and TB infection and reactivation as clinically appropriate.

Refills x 12 months unless noted otherwise here:

LINE USE/CARE ORDERS:

Start PIV/Access CVC
 Flush device per facility standard flushing procedure
 Provide nursing care per Palmetto Infusion Nursing Procedures and post procedure observation if indicated

ADVERSE REACTION & ANAPHYLAXIS ORDERS:

Administer acute infusion and anaphylaxis medications per Palmetto Infusion standing adverse reaction orders, which can be found at our website.

PRESCRIBER INFORMATION:

PROVIDER NAME:	PHONE:
ADDRESS:	FAX:
CITY, STATE, ZIP:	NPI:

PRESCRIBER SIGNATURE: (No stamp signatures)

DATE

Dispense as written/Brand medically necessary	Substitution permitted	